Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Issue 5 (9th April 2019)

• Record Type: Journal Article
• Authors: Guimarães, Patricia O.; Pokorney, Sean D.; Lopes, Renato D.; Wojdyla, Daniel M.; Gersh, Bernard J.; Giczewska, Anna; Carnicelli, Anthony; Lewis, Basil S.; Hanna, Michael; Wallentin, Lars; Vinereanu, Dragos; Alexander, John H.; Granger, Christopher B.
• Is Part Of: Clinical cardiology. Volume 42:Issue 5(2019)
• Page Start: 568
• Page End: 571
• Publication Date: 2019-04-09
• Subjects: apixaban -- atrial fibrillation -- bioprosthetic valves -- valve repair; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.23178
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract : Background: The optimal anticoagulation strategy for patients with atrial fibrillation (AF) and bioprosthetic valve (BPV) replacement or native valve repair remains uncertain. Hypothesis: We evaluated the safety and efficacy of apixaban vs warfarin in patients with AF and a history of BPV replacement or native valve repair. Methods: Using data from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) (n = 18 201), a randomized trial comparing apixaban with warfarin in patients with AF, we analyzed the subgroup of patients (n = 251) with prior valve surgery. We contacted sites by telephone to obtain additional data about prior valve surgery. Full data were available for 156 patients. The primary efficacy endpoint was stroke/systemic embolism. The primary safety endpoint was major bleeding. Treatment groups were compared using a Cox regression model. Results: In ARISTOTLE, 104 (0.6%) patients had a history of BPV replacement (n = 73 [aortic], n = 26 [mitral], n = 5 [mitral and aortic]) and 52 (0.3%) had a history of valve repair (n = 50 [mitral], n = 2 [aortic]). Among patients with BPVs, 55 were randomized to apixaban and 49 to warfarin. Among those with a history of native valve repair, 32 were randomized to apixaban and 20 to warfarin. Overall clinical event rates were low, with no significant differences between apixaban and warfarin for any outcomes. Conclusions: In patients with AF and a history of BPV replacement or repair, the safety and efficacy of apixaban compared with warfarin was consistent with results from ARISTOTLE. These data suggest that apixaban may be reasonable for patients with BPVs or prior valve repair, though future larger randomized trials are needed. ClinicalTrials.gov: NCT00412984.